Monopar Therapeutics (MNPR) Financials

Monopar Therapeutics remains a development-stage biotechnology company with no reported revenue throughout the periods provided. Its financial profile is therefore driven primarily by research spending, investment income, equity financing and cash utilization rather than operating sales.

The company’s liquidity has improved substantially since 2023. Cash and short-term investments totaled approximately $134.3 million at June 30, 2026, compared with about $53.7 million at June 30, 2025 and $8.5 million at September 30, 2023. However, much of the recent cash growth came from financing activity and investment portfolio movements, not internally generated cash flow.

Operating performance remains pressured. Monopar reported a second-quarter 2026 net loss of $5.3 million, or $0.62 per basic share, compared with a $3.9 million loss in the first quarter and a $2.5 million loss in the second quarter of 2025. Research and development expense increased to $4.8 million in Q2 2026 from $1.7 million a year earlier, indicating greater investment in its pipeline but also a higher near-term cash requirement.

• Strong liquidity position: Cash and short-term investments of approximately $134.3 million provide a meaningful financial cushion relative to quarterly operating cash burn.
• Low leverage: Total liabilities were only $4.1 million at June 30, 2026, compared with $130.9 million of total equity, limiting balance-sheet pressure from debt obligations.
• Investment income supports operations: Interest and investment income contributed $1.3 million in Q2 2026, partially offsetting operating expenses and extending the company’s cash runway.
• Recent operating cash burn was relatively stable sequentially: Net cash used in operating activities was $3.2 million in Q2 2026 versus $3.5 million in Q1 2026, despite higher research spending.
• Investment balances fluctuate significantly: The company actively purchases and sells short-term investments, producing large quarter-to-quarter swings in investing cash flow that do not necessarily reflect changes in underlying operating performance.
• Cash runway depends on clinical spending: The approximately $3.2 million quarterly operating cash outflow suggests substantial liquidity under recent spending levels, but the runway could shorten if clinical development costs accelerate.
• No operating revenue: Monopar reported zero revenue in the recent quarters provided, leaving the company dependent on financing, investment income and potential future product or partnership proceeds.
• Losses are widening compared with 2025: The Q2 2026 net loss of $5.3 million was more than double the $2.5 million loss reported in Q2 2025.
• Research spending is rising rapidly: R&D expense increased approximately 176% year over year to $4.8 million in Q2 2026, while total operating expenses rose to $6.6 million from $3.2 million in Q2 2025.
• Potential dilution remains a concern: Basic weighted-average shares outstanding rose from 3.2 million in Q1 2024 to 8.5 million in Q2 2026, reflecting the company’s reliance on equity financing to fund operations.